Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
In: Blood, Jg. 140 (2022-11-15), S. 3935-3937
Online
unknown
Zugriff:
Titel: |
Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
|
---|---|
Autor/in / Beteiligte Person: | Gupta, Vikas ; Yacoub, Abdulraheem ; Verstovsek, Srdan ; Mesa, Ruben ; Harrison, Claire ; Vannucchi, Alessandro M. ; Kiladjian, Jean-Jacques ; H. Joachim Deeg ; Fazal, Salman ; Foltz, Lynda ; Mattison, Ryan J. ; Miller, Carole B. ; Parameswaran, Vinod ; Martin-Regueira, Patricia ; Hernandez, Christopher ; Wang, Jia ; Talpaz, Moshe |
Link: | |
Zeitschrift: | Blood, Jg. 140 (2022-11-15), S. 3935-3937 |
Veröffentlichung: | American Society of Hematology, 2022 |
Medientyp: | unknown |
ISSN: | 1528-0020 (print) ; 0006-4971 (print) |
DOI: | 10.1182/blood-2022-156669 |
Schlagwort: |
|
Sonstiges: |
|